In 2021, the biologics CDMO secondary packaging market was worth around USD 1,711.7 million, and it is projected to advance at a 8.7% CAGR from 2021 to 2030, hitting USD 3,622.6 million in 2030, according to P&S Intelligence.
This development can be ascribed to the rising pharmaceutical market, snowballing making of drugs, and the increasing occurrence of numerous diseases, such as infectious diseases, chronic diseases, and hereditary disorders.
Biopharmaceutical businesses are projected to introduce numerous new products, such as treatments for diseases, to fulfill important unmet medical requirements. Also, above 7,800 products in medical development span an extensive variety of therapeutic areas, such as cardiovascular, cancer, neurology, diabetes, and others, because of the huge expenditure in research and development.
Furthermore, close to 70% of clinical-phase plans have the potential to outdo first-in-class therapies, and the quickly increasing pipeline includes products that might offer physicians novel methods of disease management.
In 2021, boxes appeared as the biggest type category in the biologics CDMO secondary packaging market, with approximately USD 1 billion in revenue, and also projected to continue with the leading spot in the future as well.
Boxes are manufactured and intended explicitly for the transport of biological items, such as freezing and controlled ambient biologics. Furthermore, such boxes are created to fulfill the uppermost standards of biological drugs’ packaging, and the special custom-made solution in order to achieve the highest level of quality, while being sensitive to worldwide environmental problems.
In 2021, on the basis of primary package types, blister packs held for the biologics CDMO secondary packaging market’s largest share of approximately 40%, and also projected to show the highest CAGR in the coming few years. This is due to they utmost significant king of packaging boxes for which the main part of the CDMOs offer secondary packaging services. Blister packing is a feasible solution for the sensitive nature of biologics, because of its adaptability and transparency.
North America held the largest market share, of above, 40%, in 2021. This is mainly because of the increasing outsourcing of drug research and development and manufacturing actions by biopharma companies.
Numerous businesses are wishing to team up with skilled packing providers that offer up-to-date packaging solutions and have the vital capabilities to create unique packing designs in a lucrative and time-efficient manner.
The APAC industry is projected to experience the fastest development in the coming few years. Mainly because of the increasing occurrence of chronic diseases, the growing concentration of businesses on contract engineering, and key players showing robust attention to facility extension in the APAC.
Hence, the rising pharmaceutical market, snowballing making of drugs, and the increasing occurrence of numerous diseases, such as infectious diseases, chronic diseases, and hereditary disorders, are the major factors, contributing to the growth of the biologics CDMO secondary packaging industry.